MedTrace Logo

Canadian Ticagrelor Survey

NCT01757483 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 244

Last updated 2015-12-09

No results posted yet for this study

Summary

This study is designed to evaluate the effectiveness of the current ticagrelor risk minimisation strategy in Canada through a prescriber knowledge and understanding (KAU) survey of selected important identified safety concerns (i.e., bleeding, dyspnea and drug interactions) and ASA dosage.

Conditions

  • Acute Coronary Syndrome

Sponsors & Collaborators

Principal Investigators

  • Yola Moride, PhD · Université de Montréal

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01757483 on ClinicalTrials.gov